Bruce Koch obtained his PhD at Harvard Medical School working on GPCR signaling mechanisms and was a postdoctoral scholar in Randy Schekman’s lab at the University of California, Berkeley working on the role of heat shock proteins in protein secretion. He then spent 19 years in the pharmaceutical industry, working first at Syntex and then at Roche. He began his career at Syntex developing and running in vitro assays to support Lead Optimization. After that, he spent 6 years working to discover selective voltage-gated sodium channel blockers for the treatment of neuropathic pain. He then joined the High-Throughput Screening Group as an assay developer and later headed the group while also leading a program to discover ion channel blockers to treat MS. He later became Director of Discovery Technologies for the Roche Palo Alto Site and Global Coordinator of High-Throughput Screening. Since 2010, he has been an advisor to the Stanford SPARK Program. In 2011, he joined the Stanford University School of Medicine to the shared scientific facilities. In 2020, he joined Sarafan ChEM-H as Director of the High-Throughput Screening Knowledge Center, a collaborative center with the Department of Chemical and Systems Biology.